GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Asset Turnover

Bausch Health (Bausch Health) Asset Turnover : 0.09 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Bausch Health Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bausch Health's Revenue for the three months ended in Dec. 2023 was $2,408 Mil. Bausch Health's Total Assets for the quarter that ended in Dec. 2023 was $27,207 Mil. Therefore, Bausch Health's Asset Turnover for the quarter that ended in Dec. 2023 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Bausch Health's annualized ROE % for the quarter that ended in Dec. 2023 was 14.17%. It is also linked to ROA % through Du Pont Formula. Bausch Health's annualized ROA % for the quarter that ended in Dec. 2023 was -0.57%.


Bausch Health Asset Turnover Historical Data

The historical data trend for Bausch Health's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Asset Turnover Chart

Bausch Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.25 0.28 0.30 0.33

Bausch Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.09 0.09 0.09

Competitive Comparison of Bausch Health's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch Health's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bausch Health's Asset Turnover falls into.



Bausch Health Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bausch Health's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=8757/( (25686+27350)/ 2 )
=8757/26518
=0.33

Bausch Health's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=2408/( (27064+27350)/ 2 )
=2408/27207
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bausch Health  (NYSE:BHC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bausch Health's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-156/-1101
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-156 / 9632)*(9632 / 27207)*(27207/ -1101)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1.62 %*0.354*-24.7112
=ROA %*Equity Multiplier
=-0.57 %*-24.7112
=14.17 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bausch Health's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-156/27207
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-156 / 9632)*(9632 / 27207)
=Net Margin %*Asset Turnover
=-1.62 %*0.354
=-0.57 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bausch Health Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bausch Health's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bausch Health (Bausch Health) Business Description

Traded in Other Exchanges
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Executives
Seana Carson officer: EVP, General Counsel 400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi officer: SVP, Controller & CAO 727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan director C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh officer: EVP, Chief Financial Officer 1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr director, officer: U.S. President-Pharma Business C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon officer: Pres&Co-Head Bausch&Lomb/Int'l C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch officer: SVP, Controller and CAO C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann officer: EVP AND GENERAL COUNSEL C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky officer: EVP & Chief Financial Officer C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller director 16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries officer: EVP, COMPANY GROUP CHAIRMAN C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p. director, other: See remarks ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129

Bausch Health (Bausch Health) Headlines

From GuruFocus